Only ivosidenib, a small-molecule IDH1 inhibitor approved by the FDA in 2018, is offered in an expanded access program in r/r AML with an IDH1R132 mutation to children ≥12 years of age (NCT03245424). The gene discussed is IDH1; the disease is acute myeloid leukemia.